Individualised Prediction of Drug Resistance and Seizure Recurrence after Medication Withdrawal in People with Juvenile Myoclonic Epilepsy: A Systematic Review and Individual Participant Data Meta-Analysis
Remi Stevelink,Dania Al-Toma,Floor E Jansen,Herm J Lamberink,Ali A Asadi-Pooya,Mohsen Farazdaghi,Gonçalo Cação,Sita Jayalakshmi,Anuja Patil,Çiğdem Özkara,Şenay Aydın,Joanna Gesche,Christoph P Beier,Linda J Stephen,Martin J Brodie,Gopeekrishnan Unnithan,Ashalatha Radhakrishnan,Julia Höfler,Eugen Trinka,Roland Krause,EpiPGX Consortium,Emanuele Cerulli Irelli,Carlo Di Bonaventura,Jerzy P Szaflarski,Laura E Hernández-Vanegas,Monica L Moya-Alfaro,Yingying Zhang,Dong Zhou,Nicola Pietrafusa,Nicola Specchio,Giorgi Japaridze,Sándor Beniczky,Mubeen Janmohamed,Patrick Kwan,Marte Syvertsen,Kaja K Selmer,Bernd J Vorderwülbecke,Martin Holtkamp,Lakshminarayanapuram G Viswanathan,Sanjib Sinha,Betül Baykan,Ebru Altindag,Felix von Podewils,Juliane Schulz,Udaya Seneviratne,Alejandro Viloria-Alebesque,Ioannis Karakis,Wendyl J D'Souza,Josemir W Sander,Bobby P C Koeleman,Willem M Otte,Kees P J Braun
DOI: https://doi.org/10.1016/j.eclinm.2022.101732
IF: 15.1
2022-01-01
EClinicalMedicine
Abstract:Background:A third of people with juvenile myoclonic epilepsy (JME) are drug-resistant. Three-quarters have a seizure relapse when attempting to withdraw anti-seizure medication (ASM) after achieving seizure-freedom. It is currently impossible to predict who is likely to become drug-resistant and safely withdraw treatment. We aimed to identify predictors of drug resistance and seizure recurrence to allow for individualised prediction of treatment outcomes in people with JME. Methods:We performed an individual participant data (IPD) meta-analysis based on a systematic search in EMBASE and PubMed - last updated on March 11, 2021 - including prospective and retrospective observational studies reporting on treatment outcomes of people diagnosed with JME and available seizure outcome data after a minimum one-year follow-up. We invited authors to share standardised IPD to identify predictors of drug resistance using multivariable logistic regression. We excluded pseudo-resistant individuals. A subset who attempted to withdraw ASM was included in a multivariable proportional hazards analysis on seizure recurrence after ASM withdrawal. The study was registered at the Open Science Framework (OSF; https://osf.io/b9zjc/). Findings:Our search yielded 1641 articles; 53 were eligible, of which the authors of 24 studies agreed to collaborate by sharing IPD. Using data from 2518 people with JME, we found nine independent predictors of drug resistance: three seizure types, psychiatric comorbidities, catamenial epilepsy, epileptiform focality, ethnicity, history of CAE, family history of epilepsy, status epilepticus, and febrile seizures. Internal-external cross-validation of our multivariable model showed an area under the receiver operating characteristic curve of 0·70 (95%CI 0·68-0·72). Recurrence of seizures after ASM withdrawal (n = 368) was predicted by an earlier age at the start of withdrawal, shorter seizure-free interval and more currently used ASMs, resulting in an average internal-external cross-validation concordance-statistic of 0·70 (95%CI 0·68-0·73). Interpretation:We were able to predict and validate clinically relevant personalised treatment outcomes for people with JME. Individualised predictions are accessible as nomograms and web-based tools. Funding:MING fonds.